Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceuticals limited - deflazacort - tablets - 30 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceuticals limited - deflazacort - tablets - 1mg milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceuticals limited - deflazacort - tablets - 30 milligram

Canada - English - Health Canada

emd serono, a division of emd inc., canada - clomiphene citrate - tablet - 50mg - clomiphene citrate 50mg - estrogen agonist-antagonists

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

vitamode sdn.bhd - hydrocortisone -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

vitamode sdn.bhd - hydrocortisone -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

orion pharma (my) sdn. bhd. - hydrocortisone -

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - triamcinolone - tablets - triamcinolone 4 mg - triamcinolone - triamcinolone - rheumatology: - active phases of systemic vasculitis: panarteritis nodosa (in patients with concomitant positive hepatitis b serology, the duration of treatment should be restricted to two weeks), polymyalgia rheumatica (pmr), pmr with giant cell arteritis, arteritis temporalis with acute visual loss;- active phases of systemic rheumatic disease: systemic lupus erythematosus, mixed connective tissue disease;- severe progressive forms of active rheumatoid arthritis, e.g. rapidly destructive forms and/or with extra-articular manifestations;- other forms of inflammatory rheumatic arthritis, provided that the severity of symptoms requires it and non-steroidal anti-inflammatory drugs (nsaids) cannot be used:spondylarthritis (ankylosing spondylitis with involvement of peripheral joints, psoriatic arthritis, enteropathic arthropathy with high inflammatory activity);- reactive forms of arthritis;- arthritis in sarcoidosis;- severe systemic form of juvenile idiopathic arthritis (still’s disease) or with iridocyclitis refractory to topical treatment.pulmonary and respiratory tract disorders: - bronchial asthma:for the long-term treatment of severe chronic asthma (category 4) and for treatment of exacerbations in adults and children.- chronic obstructive pulmonary disease (copd):for short-term treatment (max. 14 days) of exacerbations;- upper respiratory tract disorders:for short-term treatment of severe forms of allergic rhinitis in adults after failure of all other treatment alternatives, including topical glucocorticoids.dermatology: - oral initial treatment of extensive, severe, acute skin conditions responsive to glucocorticoids, such as: allergic skin disease (e.g. acute urticaria, contact dermatitis, drug eruption), atopic eczema (acute exacerbations or extensive weeping eczema), pemphigus vulgaris.nephrology: - minimal change glomerulonephritis;- extracapillary proliferative glomerulonephritis (rapidly progressive glomerulonephritis), generally in combination with cytostatics, tapering and ending treatment in goodpasture’s syndrome; for all other forms, long-term continuation of treatment;- idiopathic retroperitoneal fibrosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciclosporin, quantity: 25 mg - capsule, soft - excipient ingredients: gelatin; iron oxide black; polysorbate 20; purified water; ethyl lactate; sorbitan oleate; titanium dioxide; peg-40 hydrogenated castor oil; glycerol; tricaprin; lecithin - ciclosporin is indicated: ? as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. ? for induction and/or maintenance of remission in the nephrotic syndrome. ciclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see section 4.4 special warnings and precautions for use). ? for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. ? in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. ? for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.,careful monitoring of all ciclosporin-treated patients is mandatory. ciclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see section 4.4 special warnings and precautions for use).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: gelatin; titanium dioxide; tricaprin; sorbitan oleate; lecithin; purified water; ethyl lactate; polysorbate 20; iron oxide black; peg-40 hydrogenated castor oil; glycerol - ciclosporin is indicated: ? as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. ? for induction and/or maintenance of remission in the nephrotic syndrome. ciclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see section 4.4 special warnings and precautions for use). ? for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. ? in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. ? for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.,careful monitoring of all ciclosporin-treated patients is mandatory. ciclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see section 4.4 special warnings and precautions for use).